Severe early bilateral macular edema following fingolimod therapy

Oscar Jim Michael Coppes, Ismael Gutierrez, Anthony T. Reder, Susan Ksiazek, Jacqueline Bernard

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We report a case of bilateral macular edema (ME) within 10 days of starting fingolimod 0.5 mg therapy in a patient with Multiple Sclerosis (MS). The complication resolved without treatment as demonstrated by sequential Optical Coherence Tomography (OCT). Fingolimod is a sphingosine-1-phosphate receptor modulator that reduces lymphocyte presence in the CNS. In pivotal trials, ME, a known complication of fingolimod, typically occurred unilaterally with onset at approximately 3 months. A 60 y/o AA female, diagnosed with MS in 1977, started oral fingolimod treatment on 05/31/2011. Baseline screening with OCT and ophthalmology evaluation showed no ME. On 06/10, she developed bilateral blurry vision and discontinued fingolimod. On 06/27, OCT revealed severe bilateral ME. Later OCT exams showed a progressive decrease in Central Foveal Thickness (CFT) and Macular Volume (MV), without specific treatment other than discontinuation of fingolimod. On 7/27, CFT, MV, and Visual Acuity (VA) were similar to baseline. This is the first reported case of bilateral, early onset ME following fingolimod treatment at the current FDA-approved dose of 0.5 mg. Diabetes, a known risk factor for ME, may have contributed to her early, bilateral involvement. Our case provides further support for earlier OCT, in conjunction with ophthalmic examinations, for at-risk patients on fingolimod, and suggests that cessation of fingolimod may be associated with resolution of ME.

Original languageEnglish (US)
Pages (from-to)256-258
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Volume2
Issue number3
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

Macular Edema
Optical Coherence Tomography
Therapeutics
Multiple Sclerosis
Lysosphingolipid Receptors
Fingolimod Hydrochloride
Ophthalmology
Visual Acuity
Lymphocytes

Keywords

  • Macular edema
  • Multiple sclerosis
  • Optic nerve
  • Optical coherence tomography
  • Retina
  • Vision loss

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Severe early bilateral macular edema following fingolimod therapy. / Coppes, Oscar Jim Michael; Gutierrez, Ismael; Reder, Anthony T.; Ksiazek, Susan; Bernard, Jacqueline.

In: Multiple Sclerosis and Related Disorders, Vol. 2, No. 3, 01.07.2013, p. 256-258.

Research output: Contribution to journalArticle

Coppes, Oscar Jim Michael ; Gutierrez, Ismael ; Reder, Anthony T. ; Ksiazek, Susan ; Bernard, Jacqueline. / Severe early bilateral macular edema following fingolimod therapy. In: Multiple Sclerosis and Related Disorders. 2013 ; Vol. 2, No. 3. pp. 256-258.
@article{c84e310b385542e4949a53706d071a77,
title = "Severe early bilateral macular edema following fingolimod therapy",
abstract = "We report a case of bilateral macular edema (ME) within 10 days of starting fingolimod 0.5 mg therapy in a patient with Multiple Sclerosis (MS). The complication resolved without treatment as demonstrated by sequential Optical Coherence Tomography (OCT). Fingolimod is a sphingosine-1-phosphate receptor modulator that reduces lymphocyte presence in the CNS. In pivotal trials, ME, a known complication of fingolimod, typically occurred unilaterally with onset at approximately 3 months. A 60 y/o AA female, diagnosed with MS in 1977, started oral fingolimod treatment on 05/31/2011. Baseline screening with OCT and ophthalmology evaluation showed no ME. On 06/10, she developed bilateral blurry vision and discontinued fingolimod. On 06/27, OCT revealed severe bilateral ME. Later OCT exams showed a progressive decrease in Central Foveal Thickness (CFT) and Macular Volume (MV), without specific treatment other than discontinuation of fingolimod. On 7/27, CFT, MV, and Visual Acuity (VA) were similar to baseline. This is the first reported case of bilateral, early onset ME following fingolimod treatment at the current FDA-approved dose of 0.5 mg. Diabetes, a known risk factor for ME, may have contributed to her early, bilateral involvement. Our case provides further support for earlier OCT, in conjunction with ophthalmic examinations, for at-risk patients on fingolimod, and suggests that cessation of fingolimod may be associated with resolution of ME.",
keywords = "Macular edema, Multiple sclerosis, Optic nerve, Optical coherence tomography, Retina, Vision loss",
author = "Coppes, {Oscar Jim Michael} and Ismael Gutierrez and Reder, {Anthony T.} and Susan Ksiazek and Jacqueline Bernard",
year = "2013",
month = "7",
day = "1",
doi = "10.1016/j.msard.2012.11.004",
language = "English (US)",
volume = "2",
pages = "256--258",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Severe early bilateral macular edema following fingolimod therapy

AU - Coppes, Oscar Jim Michael

AU - Gutierrez, Ismael

AU - Reder, Anthony T.

AU - Ksiazek, Susan

AU - Bernard, Jacqueline

PY - 2013/7/1

Y1 - 2013/7/1

N2 - We report a case of bilateral macular edema (ME) within 10 days of starting fingolimod 0.5 mg therapy in a patient with Multiple Sclerosis (MS). The complication resolved without treatment as demonstrated by sequential Optical Coherence Tomography (OCT). Fingolimod is a sphingosine-1-phosphate receptor modulator that reduces lymphocyte presence in the CNS. In pivotal trials, ME, a known complication of fingolimod, typically occurred unilaterally with onset at approximately 3 months. A 60 y/o AA female, diagnosed with MS in 1977, started oral fingolimod treatment on 05/31/2011. Baseline screening with OCT and ophthalmology evaluation showed no ME. On 06/10, she developed bilateral blurry vision and discontinued fingolimod. On 06/27, OCT revealed severe bilateral ME. Later OCT exams showed a progressive decrease in Central Foveal Thickness (CFT) and Macular Volume (MV), without specific treatment other than discontinuation of fingolimod. On 7/27, CFT, MV, and Visual Acuity (VA) were similar to baseline. This is the first reported case of bilateral, early onset ME following fingolimod treatment at the current FDA-approved dose of 0.5 mg. Diabetes, a known risk factor for ME, may have contributed to her early, bilateral involvement. Our case provides further support for earlier OCT, in conjunction with ophthalmic examinations, for at-risk patients on fingolimod, and suggests that cessation of fingolimod may be associated with resolution of ME.

AB - We report a case of bilateral macular edema (ME) within 10 days of starting fingolimod 0.5 mg therapy in a patient with Multiple Sclerosis (MS). The complication resolved without treatment as demonstrated by sequential Optical Coherence Tomography (OCT). Fingolimod is a sphingosine-1-phosphate receptor modulator that reduces lymphocyte presence in the CNS. In pivotal trials, ME, a known complication of fingolimod, typically occurred unilaterally with onset at approximately 3 months. A 60 y/o AA female, diagnosed with MS in 1977, started oral fingolimod treatment on 05/31/2011. Baseline screening with OCT and ophthalmology evaluation showed no ME. On 06/10, she developed bilateral blurry vision and discontinued fingolimod. On 06/27, OCT revealed severe bilateral ME. Later OCT exams showed a progressive decrease in Central Foveal Thickness (CFT) and Macular Volume (MV), without specific treatment other than discontinuation of fingolimod. On 7/27, CFT, MV, and Visual Acuity (VA) were similar to baseline. This is the first reported case of bilateral, early onset ME following fingolimod treatment at the current FDA-approved dose of 0.5 mg. Diabetes, a known risk factor for ME, may have contributed to her early, bilateral involvement. Our case provides further support for earlier OCT, in conjunction with ophthalmic examinations, for at-risk patients on fingolimod, and suggests that cessation of fingolimod may be associated with resolution of ME.

KW - Macular edema

KW - Multiple sclerosis

KW - Optic nerve

KW - Optical coherence tomography

KW - Retina

KW - Vision loss

UR - http://www.scopus.com/inward/record.url?scp=84876412006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876412006&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2012.11.004

DO - 10.1016/j.msard.2012.11.004

M3 - Article

VL - 2

SP - 256

EP - 258

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

IS - 3

ER -